“…SAP has been found associated in vivo with animal and human amyloid deposits irrespective of the biochemical nature of the amyloid subunit (reviewed in [1]) and colocalizing with neurofibrillary pathology in a various neurodegenerative conditions including Creutzfedt-Jacob disease, Parkinson's and diffuse Lewy body disorders, and in the parkinsonism-dementia complex of Guam [4,[9][10][11]. SAP immunoreactivity is also commonly observed in Down's syndrome, AD, and in amyloid disorders with primarily cerebrovascular compromise such as Hereditary Cerebral Hemorrhage with Amyloidosis, Icelandic-type [12][13][14][15][16]. In AD brains, the widespread SAP immunoreactivity is evident in association with plaques and amyloid-laden vessels as well as with neurofibrillary tangles, but its presence in diffuse pre-amyloid deposits is controversial (reviewed in [4]).…”